# Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

> **NCT06253663** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Kite, A Gilead Company** · enrollment: 25 (actual)

## Conditions studied

- Relapsed/Refractory Mantle Cell Lymphoma
- Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** KTE-X19
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT06253663
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-18
- **Primary completion:** 2025-11-20
- **Final completion:** 2027-07
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06253663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06253663, "Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06253663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*